MJP Associates Inc. ADV bought a new position in CorMedix Inc. (NASDAQ:CRMD – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 25,000 shares of the company’s stock, valued at approximately $94,000.
A number of other hedge funds have also recently modified their holdings of the stock. Bank of New York Mellon Corp boosted its position in CorMedix by 16.2% during the third quarter. Bank of New York Mellon Corp now owns 151,566 shares of the company’s stock worth $561,000 after purchasing an additional 21,185 shares in the last quarter. Castellan Group purchased a new position in CorMedix during the second quarter worth approximately $98,000. Ghisallo Capital Management LLC purchased a new position in CorMedix during the second quarter worth approximately $991,000. GSG Advisors LLC boosted its position in CorMedix by 65.0% during the fourth quarter. GSG Advisors LLC now owns 49,500 shares of the company’s stock worth $177,000 after purchasing an additional 19,500 shares in the last quarter. Finally, Baystate Wealth Management LLC purchased a new position in CorMedix during the second quarter worth approximately $40,000. Hedge funds and other institutional investors own 34.18% of the company’s stock.
Insider Buying and Selling at CorMedix
In related news, CEO Joseph Todisco purchased 13,561 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The stock was purchased at an average price of $3.74 per share, with a total value of $50,718.14. Following the completion of the acquisition, the chief executive officer now owns 352,839 shares in the company, valued at $1,319,617.86. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 3.60% of the company’s stock.
CorMedix Price Performance
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the company. Truist Financial lowered their price target on CorMedix from $18.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, January 31st. Royal Bank of Canada reduced their target price on CorMedix from $10.00 to $9.00 and set an “outperform” rating for the company in a report on Wednesday, March 13th.
Check Out Our Latest Stock Analysis on CRMD
CorMedix Company Profile
CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Read More
- Five stocks we like better than CorMedix
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3 Value Stocks Too Small For Buffett’s Portfolio
- What Are Trending Stocks? Trending Stocks Explained
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- ESG Stocks, What Investors Should Know
- Disney Stock Catches 3 Upgrades In a Single Week
Want to see what other hedge funds are holding CRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CorMedix Inc. (NASDAQ:CRMD – Free Report).
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.